Sarepta Therapeutics Inc

NASDAQ:SRPT   2:01:30 PM EDT
107.88
-0.77 (-0.71%)
Regulatory, Other Pre-Announcement

Sarepta Therapeutics Announces Intent To Submit An Accelerated Approval Biologics License Application For Its Gene Therapy SRP-9001

Published: 07/29/2022 11:44 GMT
Sarepta Therapeutics Inc (SRPT) - Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for Its Gene Therapy Srp-9001 to Treat Duchenne Muscular Dystrophy.
Sarepta Therapeutics Inc - Intend to Submit a Bla for Our Srp-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy This Fall.
Sarepta Therapeutics Inc - Look Forward to a Collaborative Review Commencing This Year and Running Through First Half of 2023.